Jamie Ziggas, PharmD, BCOP

19 posts

Jamie Ziggas, PharmD, BCOP banner
Jamie Ziggas, PharmD, BCOP

Jamie Ziggas, PharmD, BCOP

@JamieZiggas

New Mama | Clinical Pharmacist, Blood and Marrow Transplantation @HopkinsMedicine | Adventurer

Baltimore, MD Katılım Nisan 2021
101 Takip Edilen70 Takipçiler
Jamie Ziggas, PharmD, BCOP retweetledi
ASTCT
ASTCT@ASTCT·
ASTCT Pharmacy SIG Steering Committee have created an FAQ document in regard to the #Fludarabine Shortage for #HCT and #CART Cell Recipients. Log in with your ASTCT account or create an account to access this resource: ow.ly/4KAA50LjjHQ
ASTCT tweet media
English
0
9
18
0
Uroosa Ibrahim
Uroosa Ibrahim@uroosaibrahim·
@JamieZiggas @ASTCT @ASTCT_Journal Thanks! Any procedures in place for expedited evaluation when they arrive for suspected CRS? To ED or infusion center or..?
Manhattan, NY 🇺🇸 English
1
0
1
0
ASTCT
ASTCT@ASTCT·
Q1: Is your center administering CAR T therapy in the outpatient setting or do you utilize a hybrid model? What is the inpatient/outpatient split? #ASTCTChat @ASTCT_Journal
ASTCT tweet media
English
7
3
14
0
ASTCT
ASTCT@ASTCT·
Q4: How are you managing fever/grade 1-2 CRS in the outpatient setting? What set of clinical criteria have centers implemented for admission to the inpatient service; and also what criteria are established for discharge once admitted? #ASTCTChat @ASTCT_Journal
ASTCT tweet media
English
3
1
10
0
Jamie Ziggas, PharmD, BCOP
Jamie Ziggas, PharmD, BCOP@JamieZiggas·
@Arpita_GandhiRX @ASTCT @ASTCT_Journal Patients come to clinic daily for lab work & assessment. If only we could do this virtually- would be the ultimate comfort for the patients! No official “checklist” for when to admit and selection is based on provider’s assessment (frailty, comorbidities, lack of care partner).
English
0
0
2
0
Jamie Ziggas, PharmD, BCOP
Jamie Ziggas, PharmD, BCOP@JamieZiggas·
@Patdemartinomd @TheWonkologist As a member of the @ASTCT Pharmacy SIG, we selected this article and developed the questions. Nothing to disclose here either! Our committee found this to be an interesting/relevant topic and wanted to learn from others regarding practices pertaining to defibrotide. #ASTCTChat
English
1
2
6
0
Patrick DeMartino
Patrick DeMartino@Patdemartinomd·
Enjoying #ASTCTChat but when ASTCT is using discussion Q like this I wonder if there needs to be financial disclosure given relationship with manufacturer. Especially given real lousy evidence re: efficacy. @TheWonkologist
ASTCT@ASTCT

10 patients started defibrotide prophylaxis during conditioning. Is your center routinely using defibrotide prophylaxis for patients at high risk for SOS? If so, what patient characteristics lead to initiating prophylaxis and how long do you continue defibrotide? #ASTCTChat

English
4
0
2
0
Jamie Ziggas, PharmD, BCOP retweetledi
ASTCT
ASTCT@ASTCT·
Mark your calendars to participate in our April Twitter chat next Wednesday, April 28! We'll be discussing the article: "Sinusoidal Obstruction Syndrome in Critically Ill Patients in the Era of Defibrotide: A Retrospective Multicenter Study ow.ly/nTv950EttCO
ASTCT tweet media
English
0
2
0
0